MULTIOMICS INTEGRATION IN ANTI-TUBERCULOSIS DRUG DISCOVERY
Despite intensive global efforts, tuberculosis remains one of the leading global health burdens, with antimicrobial resistance being a significant challenge to managing the disease. In addition, the current drugs used to treat tuberculosis suffer from limitations, such as prolonged therapeutic durat...
Saved in:
| Main Author: | Yaro Abubakar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of medical doctors Sanamed Novi Pazar
2025-05-01
|
| Series: | Sanamed |
| Subjects: | |
| Online Access: | https://new.sanamed.rs/pdf/20_1/20_1_11.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs
by: A. V. Kukurika, et al.
Published: (2023-08-01) -
Genomic decoding of drug-resistant tuberculosis transmission in Thailand over three decades
by: Naphatcha Thawong, et al.
Published: (2025-08-01) -
Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects
by: V. N. Zimina, et al.
Published: (2021-03-01) -
Epigenetic modifications are associated with mRNA and cytokine expression changes in chronic rhinosinusitis: a multiomics study from the United States
by: Devyani Lal, et al.
Published: (2025-06-01) -
Clinical characteristics and genomic epidemiological survey of tuberculosis in Wuzhou, China, 2022
by: Jianpeng Li, et al.
Published: (2025-05-01)